JPRN-UMIN000045857已完成未知
Effect of roxadustat on erythropoiesis and iron metabolism - Effect of roxadustat on erythropoiesis and iron metabolism
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have history of allergy for HIF-PH inhibitor. 2) Patients who are taking HIF-PH inhibitor. 3) Patients whose serum ferritin level 100 ng/mL and TSAT<20%. 4) Pregnant women. 5) Patients with bleeding, severe liver disease, malignant, chronic infection, autoimmune disease, polycystic kidney disease, active diabetic retinopathy. 6) Patients who are ineligible for participating the study.
研究者
相似试验
进行中（未招募）
不适用
Roxadustat and hepatic erythropoetin productioRenal anemiarenal anemia, chronic kidney disease, roxadustat, erythropoietinJPRN-jRCT1041210141Hamano Takayuki40
已完成
不适用
Effect of iron supplementation on erythropoiesis and iron-related parameters in hemodialysis patients receiving epoetin beta pegol: a randomized controlled studyPatients treated with maintenance hemodialysisJPRN-UMIN000010084Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine200
已完成
2 期
Effect of Roxadustat in management of anemia and iron regulation in cirrhosis of liver patientsCirrhosis of liver patients who is anemicAnemia, Cirrhosis of Liver, Treatment with Roxadustat a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitorTCTR20230615001Bangabandhu Sheikh Mujib Medical University75
招募中
不适用
The effect of intravenous iron therapy and erythropoesis-stimulation agent combination on renal transplant outcomesDiseases of the genitourinary systemKCT0008143Yonsei University Health System, Severance Hospital302
已完成
不适用
Metabolism of Iron and Erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD)CKD (non-dialysis, dialysis)JPRN-UMIN000001121Hyogo College of Medicine40